PRKAA2 and cancer: Therefore, the AMPK-WIP1 axis shifts from guardian in normal tissue to accomplice in cancer, indicating that therapeutic AMPK modulation must be precisely targeted to the cellular context to prevent unintended promotion of tumor resilience.